Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Wet AMD treatments can be costly, but Medicare covers some options. Knowing what Medicare covers and what it doesn’t can help you choose the best treatments for your budget. Age-related macular ...

Although AI shows significant promise in diagnosing and managing age-related macular degeneration, its efficacy is reduced by ...

Dry macular degeneration is a common eye disorder ... Dry AMD typically progresses slowly, but wet AMD can cause severe visual impairment within days or weeks of onset. In the early stages of ...

PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...

D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

Its lead compound is sozinibercept, a first-in-class VEGF-C/D ‘trap’ inhibitor intended for combination with anti-VEGF-A therapies for the treatment of wet AMD and Diabetic Macular Edema ('DME').

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

“OCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet age-related macular degenerati ... leaders MALVERN, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE ...

This is the first registrational clinical trial of AXPAXLI in wet age-related macular degeneration ... are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ocular ...